Effect of individualised homoeopathic medicines on inflammation in patients with type 2 diabetes mellitus

Effect of individualised homoeopathic medicines on systemic inflammation in type 2 diabetes mellitus-A biomarker based study using high sensitivity c-reactive protein - Nil

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/04/108171

Enrollment

Registered

2026-04-10

Start date

Unknown

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Individualised Homoeopathic Medicines: Individualised Homoeopathic Medicines in various potencies according to totality of symptoms and principles of homoeopathy for 4 months Control In

Eligibility

Inclusion criteria

Inclusion criteria: 1.Cases satisfying the working case definition (FBS levels in between 126 and 250 mg/dL, HbA1C levels in between 6.5 and 10 % and hsCRP levels more than 1mg/L 2.Individuals of both sexes within the age limit of 30-65 years

Exclusion criteria

Exclusion criteria: 1.Patients with hsCRP levels more than 7 mg/L 2. Patients with complications of type 2 diabetes mellitus like nephropathy, retinopathy 3. Patients with severe infections, chronic inflammatory conditions, connective tissue disorders and cardiac diseases 4. Diagnosed cases of Type 1 Diabetes Mellitus 5. Patients with BP more than 160/100 mmHg 6. Patients with total cholesterol more than 300 mg/dL 7. Known cases of malignancies 8. Pregnant, lactating women 9. Patients taking insulin and antidiabetic medicines

Design outcomes

Primary

Measure	Time frame
Changes in hsCRP levelsTimepoint: Measured at base line and after 4 months of treatment	—

Secondary

Measure	Time frame
1. Changes in HbAlc levels 2. Changes in FBS levels 3. Correlation between HbA1C and hsCRP levels by comparing their values 4. Correlation between FBS and hsCRP levels by comparing their valuesTimepoint: 1.Measured at baseline and after 4 months of treatment 2.Measured at baseline and after 4 months of treatment 3.Measured at baseline and after 4 months of treatment 4.Measured at baseline and after 4 months of treatment	—

Measure

Time frame

1. Changes in HbAlc levels 2. Changes in FBS levels 3. Correlation between HbA1C and hsCRP levels by comparing their values 4. Correlation between FBS and hsCRP levels by comparing their valuesTimepoint: 1.Measured at baseline and after 4 months of treatment 2.Measured at baseline and after 4 months of treatment 3.Measured at baseline and after 4 months of treatment 4.Measured at baseline and after 4 months of treatment

—

Countries

India

Contacts

Public ContactDr Thara K

Government Homoeopathic Medical College, Kozhikode

drthararaj@gmail.com9745245755

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026